tetano
Editor, Senior Moderator
Biotechnol J. 2018 Feb 22. doi: 10.1002/biot.201700749. [Epub ahead of print]
[h=1]Exosomes enter vaccine development: Strategies meeting global challenges of emerging infections.[/h] Jungbauer A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] New approaches for vaccination must be developed in order to meet the grand challenges for emerging infectious diseases. Exosomes now enter vaccine development and these are strategies are meeting these global challenges, as demonstrated by Anticoli et al, in this issue of Biotechnology Journal [1] Using exosome vaccines has been now been demonstrated in-vivo for several viruses such as Ebola Virus VP24, VP40 and NP, Influenza Virus NP, Crimean-Congo Hemorrhagic Fever NP, West Nile Virus NS3, and Hepatitis C Virus NS3. Now this technology must be tested in clinics.
PMID: 29469213 DOI: 10.1002/biot.201700749
[h=1]Exosomes enter vaccine development: Strategies meeting global challenges of emerging infections.[/h] Jungbauer A[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] New approaches for vaccination must be developed in order to meet the grand challenges for emerging infectious diseases. Exosomes now enter vaccine development and these are strategies are meeting these global challenges, as demonstrated by Anticoli et al, in this issue of Biotechnology Journal [1] Using exosome vaccines has been now been demonstrated in-vivo for several viruses such as Ebola Virus VP24, VP40 and NP, Influenza Virus NP, Crimean-Congo Hemorrhagic Fever NP, West Nile Virus NS3, and Hepatitis C Virus NS3. Now this technology must be tested in clinics.
PMID: 29469213 DOI: 10.1002/biot.201700749